AstraZeneca Targets $80 Billion in Total Revenue by 2030
AstraZeneca aims to grow revenue by about 75% to $80 billion by 2030, it said on Tuesday, boosted by the expected launch of 20 new medicines and through growth in its existing oncology, biopharmaceuticals and rare disease portfolio. The Anglo-Swedish drugmaker had reported total revenue of $45.81 billion last year and earlier expected to launch … Read more